Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
miércoles, octubre 21
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Nyxoah SA
NYXH
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$0.8950
-0.045
-4.79%
Últ. Act.: Oct 21, 9:28 AM
$0.9372
-0.0028
-0.3%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Comparar
Informe de acciones
Privacy Manager
Nyxoah Financials
Nyxoah (NYXH) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Nyxoah Lowers FY2026 Sales Guidance from $42.156M-$46.840M to $41.852M-$46.502M vs $44.410M Est
Nyxoah (NASDAQ:NYXH) lowers FY2026 sales outlook from $42.156 million-$46.840 million to $41.852 million-$46.502 million vs $44.410 million estimate.
Benzinga Newsdesk
PRO
Nyxoah Q2 EPS $(0.67) Misses $(0.47) Estimate, Sales $8.922M Miss $9.030M Estimate
Nyxoah (NASDAQ:NYXH) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate of $(0.47) by 42.55 percent. This is a 8.06 percent decrease over losses of $(0.62) per share from the same
Benzinga Newsdesk
PRO
Nyxoah Reports Preliminary Q2 Global Net Revenue Of ~€7.7M, Reiterates FY26 Global Net Revenue Range €36M - €40M
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through
Benzinga Newsdesk
PRO
Nyxoah Sees FY2026 Sales $42.156M-$46.840M vs $37.200M Est
Nyxoah (NASDAQ:NYXH) sees FY2026 sales of $42.156 million-$46.840 million vs $37.200 million analyst estimate.
Benzinga Newsdesk
PRO
Nyxoah Q1 EPS $(0.43) Beats $(0.54) Estimate, Sales $7.462M Beat $7.130M Estimate
Nyxoah (NASDAQ:NYXH) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.54) by 20.37 percent. This is a 31.75 percent increase over losses of $(0.63) per share from the same
Benzinga Newsdesk
Earnings Scheduled For May 12, 2026
Benzinga Insights
